Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC1012 for Prevention of AML Relapse After Allo-HSCT
NCT05858814Phase 2Recruiting
- Sponsor
- Guangdong Ruishun Biotechnology Co., Ltd.
- Start
- May 2023
- Primary completion
- May 2024
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of RC1012 in acute myeloid leukemia (AML) (3 arms), sponsored by Guangdong Ruishun Biotechnology Co., Ltd. Primary endpoints: Dose-Limiting Toxicity at 28 days, Maximum Tolerated Dose at 28 days and 1 more. Started May 2023; status: recruiting.
02
Drugs
RC1012
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05858814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05858814.